SV

Street Verdict

Analyst Scorecard

A record of what CLSA Analysis said publicly, with the source. Not advice.

Pending — not yet graded
“CLSA expects pharma stocks to recover, as the sector remains exempt from the new US tariffs and the market had already priced in a 10% tariff. This indicates a bullish outlook for the sector as a key overhang has been removed.”

CLSA Analysis’s track record (trackable calls only): 59 graded calls · 95% CI 16–38%

Nifty PharmaBullishCalled 03 Apr 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee CLSA Analysis’s full track record